Indeed, targeting alarmins during asthma has shown great potential, with a range of novel biologics currently in clinical trials for asthma, such as itepekimab targeting IL‐33 [52], astegolimab targeting IL‐33 receptor ST2 [53], or tezepelumab targeting TSLP [54, 55]. The gene discussed is TSLP; the disease is asthma.